Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.
Publication
, Journal Article
Rini, BI; Halabi, S; Rosenberg, J; Stadler, WM; Vaena, DA; Atkins, JN; Picus, J; Czaykowski, P; Dutcher, J; Small, EJ
Published in: J Clin Oncol
May 20, 2009
LBA5019 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text].
Duke Scholars
Published In
J Clin Oncol
EISSN
1527-7755
Publication Date
May 20, 2009
Volume
27
Issue
15_suppl
Start / End Page
LBA5019
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Rini, B. I., Halabi, S., Rosenberg, J., Stadler, W. M., Vaena, D. A., Atkins, J. N., … Small, E. J. (2009). Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol, 27(15_suppl), LBA5019.
Rini, B. I., S. Halabi, J. Rosenberg, W. M. Stadler, D. A. Vaena, J. N. Atkins, J. Picus, P. Czaykowski, J. Dutcher, and E. J. Small. “Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): LBA5019.
Rini BI, Halabi S, Rosenberg J, Stadler WM, Vaena DA, Atkins JN, et al. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol. 2009 May 20;27(15_suppl):LBA5019.
Rini, B. I., et al. “Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.” J Clin Oncol, vol. 27, no. 15_suppl, May 2009, p. LBA5019.
Rini BI, Halabi S, Rosenberg J, Stadler WM, Vaena DA, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol. 2009 May 20;27(15_suppl):LBA5019.
Published In
J Clin Oncol
EISSN
1527-7755
Publication Date
May 20, 2009
Volume
27
Issue
15_suppl
Start / End Page
LBA5019
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences